Skip to main content
Erschienen in: Digestive Diseases and Sciences 5/2007

01.05.2007 | Review Article

The Use of Cytokeratin Stain to Distinguish Barrett’s Esophagus from Contiguous Tissues: A Systematic Review

verfasst von: Zhannat Nurgalieva, Angus Lowrey, Hashem B. El-Serag

Erschienen in: Digestive Diseases and Sciences | Ausgabe 5/2007

Einloggen, um Zugang zu erhalten

Abstract

Our objective was to systematically review the existing literature regarding the use of cytokeratin (CK) stain in differentiating Barrett’s esophagus (BE) from tissues of the gastric cardia, corpus, or antrum, with or without intestinal metaplasia (IM). Pubmed was searched for full publications in English (1983–2005) addressing the use of CK for differentiation of BE from contiguous tissues. Information was collected on the study sample, blinding, the methods used for CK staining, and for defining and applying the gold standard tests. Test characteristics were obtained or calculated. Sixteen studies (containing 46 comparisons) met the inclusion and exclusion criteria. Immunostaining for CK 7 and 20 was generally highly specific in distinguishing long-segment BE from antrum IM, fundus IM, or noncardiac gastric IM; 27 comparisons showed statistically significant differences. However, only 8 of 15 comparisons (6 of 12 studies) reported significant differences in CK staining patterns between BE and gastric cardia IM with a high sensitivity (89%–100%) and specificity (83%–100%) for long-segment BE and lower estimates for short-segment BE, while the other seven comparisons showed no significant differences and a very low sensitivity. Examination by a blinded pathologist was reported in five of six positive studies and in only one of six of the negative studies. In addition, variation in the patient populations, use of surgical resection versus endoscopic biopsies, and biopsy sampling technique in endoscopic studies may have accounted for these differences. Finally, two studies did not find significant differences in CK staining patterns between BE and normal cardiac mucosa. In conclusions, CK immunostaining has not performed well in differentiating BE, especially short-segment BE, from cardia IM. There seems to be a spectrum bias where the accuracy varies with different tested populations. CK immunostaining distinguished well between BE and IM in noncardiac segments of the stomach; however, these comparisons are not clinically relevant.
Literatur
1.
Zurück zum Zitat Shaheen N, Ransohoff DF (2002) Gastroesophageal reflux, Barrett esophagus, and esophageal cancer: scientific review. JAMA 287(15):1972–1981PubMedCrossRef Shaheen N, Ransohoff DF (2002) Gastroesophageal reflux, Barrett esophagus, and esophageal cancer: scientific review. JAMA 287(15):1972–1981PubMedCrossRef
2.
Zurück zum Zitat Winters C Jr, Spurling TJ, Chobanian SJ, et al. (1987) Barrett’s esophagus. A prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology 92(1):118–124PubMed Winters C Jr, Spurling TJ, Chobanian SJ, et al. (1987) Barrett’s esophagus. A prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology 92(1):118–124PubMed
3.
Zurück zum Zitat Sampliner RE (2002) Barrett’s esophagus, a complication of GERD. Curr Treat Options Gastroenterol 5(1):45–50PubMed Sampliner RE (2002) Barrett’s esophagus, a complication of GERD. Curr Treat Options Gastroenterol 5(1):45–50PubMed
4.
Zurück zum Zitat El Serag HB (2002) The epidemic of esophageal adenocarcinoma. Gastroenterol Clin North Am 31(2):421–440 El Serag HB (2002) The epidemic of esophageal adenocarcinoma. Gastroenterol Clin North Am 31(2):421–440
5.
Zurück zum Zitat Bonino JA, Sharma P (2005) Barrett’s esophagus. Curr Opin Gastroenterol 21(4):461–465PubMed Bonino JA, Sharma P (2005) Barrett’s esophagus. Curr Opin Gastroenterol 21(4):461–465PubMed
6.
Zurück zum Zitat Fitzgerald RC (2005) Complex diseases in gastroenterology and hepatology: GERD, Barrett’s, and esophageal adenocarcinoma. Clin Gastroenterol Hepatol 3(6):529–537PubMedCrossRef Fitzgerald RC (2005) Complex diseases in gastroenterology and hepatology: GERD, Barrett’s, and esophageal adenocarcinoma. Clin Gastroenterol Hepatol 3(6):529–537PubMedCrossRef
7.
Zurück zum Zitat El-Serag HB, Sonnenberg A, Jamal MM, Kunkel D, Crooks L, Feddersen RM (1999) Characteristics of intestinal metaplasia in the gastric cardia. Am J Gastroenterol 94(3):622–627PubMedCrossRef El-Serag HB, Sonnenberg A, Jamal MM, Kunkel D, Crooks L, Feddersen RM (1999) Characteristics of intestinal metaplasia in the gastric cardia. Am J Gastroenterol 94(3):622–627PubMedCrossRef
8.
Zurück zum Zitat Sharma P, Morales TG, Sampliner RE (1998) Short segment Barrett’s esophagus-the need for standardization of the definition and of endoscopic criteria. Am J Gastroenterol 93(7):1033–1036PubMed Sharma P, Morales TG, Sampliner RE (1998) Short segment Barrett’s esophagus-the need for standardization of the definition and of endoscopic criteria. Am J Gastroenterol 93(7):1033–1036PubMed
9.
Zurück zum Zitat Goldblum JR (2002) The significance and etiology of intestinal metaplasia of the esophagogastric junction. Ann Diagn Pathol 6(1):67–73PubMedCrossRef Goldblum JR (2002) The significance and etiology of intestinal metaplasia of the esophagogastric junction. Ann Diagn Pathol 6(1):67–73PubMedCrossRef
10.
Zurück zum Zitat Moll R (1997) Cytokeratins in the histological diagnosis of malignant tumors. Int J Biol Markers 9:63–69 Moll R (1997) Cytokeratins in the histological diagnosis of malignant tumors. Int J Biol Markers 9:63–69
11.
Zurück zum Zitat Moll R, Franke WW, Schiller D (1982) The catalogue of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 31:11–24PubMedCrossRef Moll R, Franke WW, Schiller D (1982) The catalogue of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 31:11–24PubMedCrossRef
12.
Zurück zum Zitat Ormsby AH, Goldblum JR, Rice TW, Richter JE, Falk GW, Vaezi MF, Gramlich TL (1999) Cytokeratin subsets can reliably distinguish Barrett’s esophagus from intestinal metaplasia of the stomach. Hum Pathol 30(3):288–294PubMedCrossRef Ormsby AH, Goldblum JR, Rice TW, Richter JE, Falk GW, Vaezi MF, Gramlich TL (1999) Cytokeratin subsets can reliably distinguish Barrett’s esophagus from intestinal metaplasia of the stomach. Hum Pathol 30(3):288–294PubMedCrossRef
13.
Zurück zum Zitat Sarbia M, Donner A, Franke C, Gabbert HE (2004) Distinction between intestinal metaplasia in the cardia and in Barrett’s esophagus: the role of histology and immunohistochemistry. Hum Pathol 35(3):371–376PubMedCrossRef Sarbia M, Donner A, Franke C, Gabbert HE (2004) Distinction between intestinal metaplasia in the cardia and in Barrett’s esophagus: the role of histology and immunohistochemistry. Hum Pathol 35(3):371–376PubMedCrossRef
14.
Zurück zum Zitat Kurtkaya-Yapicier O, Gencosmanoglu R, Avsar E, Bakirci N, Tozun N, Sav A (2003) The utility of cytokeratins 7 and 20 (CK7/20) immunohistochemistry in the distinction of short-segment Barrett esophagus from gastric intestinal metaplasia: Is it reliable? BMC Clin Pathol 3(1):5PubMedCrossRef Kurtkaya-Yapicier O, Gencosmanoglu R, Avsar E, Bakirci N, Tozun N, Sav A (2003) The utility of cytokeratins 7 and 20 (CK7/20) immunohistochemistry in the distinction of short-segment Barrett esophagus from gastric intestinal metaplasia: Is it reliable? BMC Clin Pathol 3(1):5PubMedCrossRef
15.
Zurück zum Zitat Flucke U, Steinborn E, Dries V, Monig SP, Schneider PM, Thiele J, Holscher AH, Dienes HP, Baldus SE (2003) Immunoreactivity of cytokeratins (CK7, CK20) and mucin peptide core antigens (MUC1, MUC2, MUC5AC) in adenocarcinomas, normal and metaplastic tissues of the distal oesophagus, oesophago-gastric junction and proximal stomach.Histopathology 43(2):127–134PubMedCrossRef Flucke U, Steinborn E, Dries V, Monig SP, Schneider PM, Thiele J, Holscher AH, Dienes HP, Baldus SE (2003) Immunoreactivity of cytokeratins (CK7, CK20) and mucin peptide core antigens (MUC1, MUC2, MUC5AC) in adenocarcinomas, normal and metaplastic tissues of the distal oesophagus, oesophago-gastric junction and proximal stomach.Histopathology 43(2):127–134PubMedCrossRef
16.
Zurück zum Zitat DeMeester SR, Wickramasinghe KS, Lord RV, Friedman A, Balaji NS, Chandrasoma PT, Hagen JA, Peters JH, DeMeester TR (2002) Cytokeratin and DAS-1 immunostaining reveal similarities among cardiac mucosa, CIM, and Barrett’s esophagus. Am J Gastroenterol 97(10):2514–2523PubMedCrossRef DeMeester SR, Wickramasinghe KS, Lord RV, Friedman A, Balaji NS, Chandrasoma PT, Hagen JA, Peters JH, DeMeester TR (2002) Cytokeratin and DAS-1 immunostaining reveal similarities among cardiac mucosa, CIM, and Barrett’s esophagus. Am J Gastroenterol 97(10):2514–2523PubMedCrossRef
17.
Zurück zum Zitat Mohammed IA, Streutker CJ, Riddell RH (2002) Utilization of cytokeratins 7 and 20 does not differentiate between Barrett’s esophagus and gastric cardiac intestinal metaplasia. Mod Pathol 15(6):611–616PubMedCrossRef Mohammed IA, Streutker CJ, Riddell RH (2002) Utilization of cytokeratins 7 and 20 does not differentiate between Barrett’s esophagus and gastric cardiac intestinal metaplasia. Mod Pathol 15(6):611–616PubMedCrossRef
18.
Zurück zum Zitat Jovanovic I, Tzardi M, Mouzas IA, Micev M, Pesko P, Milosavljevic T, Zois M, Sganzos M, Delides G, Kanavaros P (2002) Changing pattern of cytokeratin 7 and 20 expression from normal epithelium to intestinal metaplasia of the gastric mucosa and gastroesophageal junction. Histol Histopathol 17(2):445–454 Jovanovic I, Tzardi M, Mouzas IA, Micev M, Pesko P, Milosavljevic T, Zois M, Sganzos M, Delides G, Kanavaros P (2002) Changing pattern of cytokeratin 7 and 20 expression from normal epithelium to intestinal metaplasia of the gastric mucosa and gastroesophageal junction. Histol Histopathol 17(2):445–454
19.
Zurück zum Zitat Ormsby AH, Goldblum JR, Rice TW, Richter JE, Gramlich TL (2001) The utility of cytokeratin subsets in distinguishing Barrett’s–related oesophageal adenocarcinoma from gastric adenocarcinoma. Histopathology 38(4):307–311PubMedCrossRef Ormsby AH, Goldblum JR, Rice TW, Richter JE, Gramlich TL (2001) The utility of cytokeratin subsets in distinguishing Barrett’s–related oesophageal adenocarcinoma from gastric adenocarcinoma. Histopathology 38(4):307–311PubMedCrossRef
20.
Zurück zum Zitat Glickman JN, Wang H, Das KM, Goyal RK, Spechler SJ, Antonioli D, Odze RD (2001) Phenotype of Barrett’s esophagus and intestinal metaplasia of the distal esophagus and gastroesophageal junction: an immunohistochemical study of cytokeratins 7 and 20, Das-1 and 45 MI. Am J Surg Pathol 25(1):87–94CrossRef Glickman JN, Wang H, Das KM, Goyal RK, Spechler SJ, Antonioli D, Odze RD (2001) Phenotype of Barrett’s esophagus and intestinal metaplasia of the distal esophagus and gastroesophageal junction: an immunohistochemical study of cytokeratins 7 and 20, Das-1 and 45 MI. Am J Surg Pathol 25(1):87–94CrossRef
21.
Zurück zum Zitat Couvelard A, Cauvin JM, Goldfain D, Rotenberg A, Robaszkiewicz M, Flejou JF, Groupe d’Etude l’Oesophage de Barrett (2001) Cytokeratin immunoreactivity of intestinal metaplasia at normal oesophagogastric junction indicates its aetiology. Gut 49(6):761–766 Couvelard A, Cauvin JM, Goldfain D, Rotenberg A, Robaszkiewicz M, Flejou JF, Groupe d’Etude l’Oesophage de Barrett (2001) Cytokeratin immunoreactivity of intestinal metaplasia at normal oesophagogastric junction indicates its aetiology. Gut 49(6):761–766
22.
Zurück zum Zitat El-Zimaity HM, Graham DY (2001) Cytokeratin subsets for distinguishing Barrett’s esophagus from intestinal metaplasia in the cardia using endoscopic biopsy specimens. Am J Gastroenterol 96(5):1378–1382PubMedCrossRef El-Zimaity HM, Graham DY (2001) Cytokeratin subsets for distinguishing Barrett’s esophagus from intestinal metaplasia in the cardia using endoscopic biopsy specimens. Am J Gastroenterol 96(5):1378–1382PubMedCrossRef
23.
Zurück zum Zitat Gulmann C, Shaqaqi OA, Grace A, Leader M, Patchett S, Butler D, Kay E (2004) Cytokeratin 7/20 and MUC1, 2, 5AC, and 6 expression patterns in Barrett’s esophagus and intestinal metaplasia of the stomach: intestinal metaplasia of the cardia is related to Barrett’s esophagus. Appl Immunohistochem Mol Morphol 12(2):142–147PubMed Gulmann C, Shaqaqi OA, Grace A, Leader M, Patchett S, Butler D, Kay E (2004) Cytokeratin 7/20 and MUC1, 2, 5AC, and 6 expression patterns in Barrett’s esophagus and intestinal metaplasia of the stomach: intestinal metaplasia of the cardia is related to Barrett’s esophagus. Appl Immunohistochem Mol Morphol 12(2):142–147PubMed
24.
Zurück zum Zitat Schilling D, Spiethoff A, Rosenbaum A, Hartmann D, Eickhoff A, Jakobs R, Weickert U, Rebe M, Bohrer MH, Riemann JF (2005) Does cytokeratin7/20 immunoreactivity help to distinguish Barrett’s esophagus from gastric intestinal metaplasia? Results of a prospective study of 75 patients. Pathol Res Pract 200(11–12):801–805PubMedCrossRef Schilling D, Spiethoff A, Rosenbaum A, Hartmann D, Eickhoff A, Jakobs R, Weickert U, Rebe M, Bohrer MH, Riemann JF (2005) Does cytokeratin7/20 immunoreactivity help to distinguish Barrett’s esophagus from gastric intestinal metaplasia? Results of a prospective study of 75 patients. Pathol Res Pract 200(11–12):801–805PubMedCrossRef
25.
Zurück zum Zitat Wallner B, Sylvan A, Janunger KG, Bozoky B, Stenling R (2001) Immunohistochemical markers for Barrett’s esophagus and associations to esophageal Z–line appearance. Scand J Gastroenterol 36(9):910–915PubMedCrossRef Wallner B, Sylvan A, Janunger KG, Bozoky B, Stenling R (2001) Immunohistochemical markers for Barrett’s esophagus and associations to esophageal Z–line appearance. Scand J Gastroenterol 36(9):910–915PubMedCrossRef
26.
Zurück zum Zitat Yagi K, Nakamura A, Sekine A (2005) Cytokeratin immunoreactivity patterns in short-segment Barrett’s esophagus in Japanese patients. J Gastroenterol Hepatol 20(6):929–934PubMedCrossRef Yagi K, Nakamura A, Sekine A (2005) Cytokeratin immunoreactivity patterns in short-segment Barrett’s esophagus in Japanese patients. J Gastroenterol Hepatol 20(6):929–934PubMedCrossRef
27.
Zurück zum Zitat Yim HJ, Lee SW, Choung RS, Kim YS, Kim JY, Lee HS, Song CW, Choi JH, Bak YT, Ryu HS, Hyun JH, Kim DS, Kim CH (2005) Is cytokeratin immunoreactivity useful in the diagnosis of short-segment Barrett’s oesophagus in Korea? Eur J Gastroenterol Hepatol 17(6):611–616PubMedCrossRef Yim HJ, Lee SW, Choung RS, Kim YS, Kim JY, Lee HS, Song CW, Choi JH, Bak YT, Ryu HS, Hyun JH, Kim DS, Kim CH (2005) Is cytokeratin immunoreactivity useful in the diagnosis of short-segment Barrett’s oesophagus in Korea? Eur J Gastroenterol Hepatol 17(6):611–616PubMedCrossRef
28.
Zurück zum Zitat Shearer C, Going J, Neilson L, Mackay C, Stuart RC (2005) Cytokeratin 7 and 20 expression in intestinal metaplasia of the distal oesophagus: relationship to gastro–oesophageal reflux disease. Histopathology 47(3):268–275PubMedCrossRef Shearer C, Going J, Neilson L, Mackay C, Stuart RC (2005) Cytokeratin 7 and 20 expression in intestinal metaplasia of the distal oesophagus: relationship to gastro–oesophageal reflux disease. Histopathology 47(3):268–275PubMedCrossRef
29.
Zurück zum Zitat Ormsby AH, Vaezi MF, Richter JE, Goldblum JR, Rice TW, Falk GW, Gramlich TL (2000) Cytokeratin immunoreactivity patterns in the diagnosis of short-segment Barrett’s esophagus. Gastroenterology 119(3):683–690 Ormsby AH, Vaezi MF, Richter JE, Goldblum JR, Rice TW, Falk GW, Gramlich TL (2000) Cytokeratin immunoreactivity patterns in the diagnosis of short-segment Barrett’s esophagus. Gastroenterology 119(3):683–690
30.
Zurück zum Zitat Boch JA, Shields HM, Antonioli DA, Zwas F, Sawhney RA, Trier JS (1997) Distribution of cytokeratin markers in Barrett’s specialized columnar epithelium. Gastroenterology 112(3):760–765PubMedCrossRef Boch JA, Shields HM, Antonioli DA, Zwas F, Sawhney RA, Trier JS (1997) Distribution of cytokeratin markers in Barrett’s specialized columnar epithelium. Gastroenterology 112(3):760–765PubMedCrossRef
31.
Zurück zum Zitat Piazuelo MB, Haque S, Delgado A, Du JX, Rodriguez F, Correa P (2004) Phenotypic differences between esophageal and gastric intestinal metaplasia. Mod Pathol 17(1):62–74PubMedCrossRef Piazuelo MB, Haque S, Delgado A, Du JX, Rodriguez F, Correa P (2004) Phenotypic differences between esophageal and gastric intestinal metaplasia. Mod Pathol 17(1):62–74PubMedCrossRef
32.
Zurück zum Zitat Jaeschke R, Guyatt G, Sackett DL (1994) Users’ guides to the medical literature. III. How to use an article about a diagnostic test. A. Are the results of the study valid? Evidence–Based Medicine Working Group. JAMA 271(5):389–391PubMedCrossRef Jaeschke R, Guyatt G, Sackett DL (1994) Users’ guides to the medical literature. III. How to use an article about a diagnostic test. A. Are the results of the study valid? Evidence–Based Medicine Working Group. JAMA 271(5):389–391PubMedCrossRef
33.
Zurück zum Zitat Zwas F, Shields HM, Doos WG (1986) Scanning electron microscopy of Barrett’s epithelium and its correlation with light microscopy and mucin stains. Gastroenterology 90:1932–1941PubMed Zwas F, Shields HM, Doos WG (1986) Scanning electron microscopy of Barrett’s epithelium and its correlation with light microscopy and mucin stains. Gastroenterology 90:1932–1941PubMed
34.
Zurück zum Zitat Glickman JN, Ormsby AH, Gramlich TL, Goldblum JR, Odze RD (2005) Interinstitutional variability and effect of tissue fixative on the interpretation of a Barrett cytokeratin 7/20 immunoreactivity pattern in Barrett esophagus. Hum Pathol 36(1):58–65PubMedCrossRef Glickman JN, Ormsby AH, Gramlich TL, Goldblum JR, Odze RD (2005) Interinstitutional variability and effect of tissue fixative on the interpretation of a Barrett cytokeratin 7/20 immunoreactivity pattern in Barrett esophagus. Hum Pathol 36(1):58–65PubMedCrossRef
35.
Zurück zum Zitat Kendall C, Stone N, Shepherd N, Geboes K, Warren B, Bennett R, Barr H (2003) Raman spectroscopy, a potential tool for the objective identification and classification of neoplasia in Barrett’s oesophagus. J Pathol 200(5):602–609PubMedCrossRef Kendall C, Stone N, Shepherd N, Geboes K, Warren B, Bennett R, Barr H (2003) Raman spectroscopy, a potential tool for the objective identification and classification of neoplasia in Barrett’s oesophagus. J Pathol 200(5):602–609PubMedCrossRef
36.
Zurück zum Zitat Krishnadath KK, Reid BJ, Wang KK (2001) Biomarkers in Barrett esophagus. Mayo Clin Proc 76(4):438–446 Krishnadath KK, Reid BJ, Wang KK (2001) Biomarkers in Barrett esophagus. Mayo Clin Proc 76(4):438–446
37.
38.
Zurück zum Zitat Falk GW (2003) Cytology in Barrett’s esophagus. Gastrointest Endosc Clin N Am 13(2):335–348 Falk GW (2003) Cytology in Barrett’s esophagus. Gastrointest Endosc Clin N Am 13(2):335–348
39.
Zurück zum Zitat Dalma-Weiszhausz DD, Chicurel ME, Gingeras TR (2002) Microarrays and genetic epidemiology: a multipurpose tool for a multifaceted field. Genet Epidemiol 23(1):4–20PubMedCrossRef Dalma-Weiszhausz DD, Chicurel ME, Gingeras TR (2002) Microarrays and genetic epidemiology: a multipurpose tool for a multifaceted field. Genet Epidemiol 23(1):4–20PubMedCrossRef
40.
Zurück zum Zitat Selaru FM, Zou T, Xu Y, et al. (2002) Global gene expression profiling in Barrett’s esophagus and esophageal cancer: a comparative analysis using cDNA microarrays. Oncogene 21(3):475–478PubMedCrossRef Selaru FM, Zou T, Xu Y, et al. (2002) Global gene expression profiling in Barrett’s esophagus and esophageal cancer: a comparative analysis using cDNA microarrays. Oncogene 21(3):475–478PubMedCrossRef
Metadaten
Titel
The Use of Cytokeratin Stain to Distinguish Barrett’s Esophagus from Contiguous Tissues: A Systematic Review
verfasst von
Zhannat Nurgalieva
Angus Lowrey
Hashem B. El-Serag
Publikationsdatum
01.05.2007
Erschienen in
Digestive Diseases and Sciences / Ausgabe 5/2007
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-006-9399-3

Weitere Artikel der Ausgabe 5/2007

Digestive Diseases and Sciences 5/2007 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.